What to do about the metabolic syndrome?

Archives of Internal Medicine

Volumn 163, Issue 4, 2003, Pages 395-397

  Hill, James O ^a   Bessesen, Daniel ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROGLITAZONE;

AGE; BODY HEIGHT; BODY MASS; BODY WEIGHT; EDITORIAL; ETHNIC DIFFERENCE; HEART DISEASE; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT;

AGE FACTORS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; NUTRITION SURVEYS; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 0037463605     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.4.395     Document Type: Editorial

References (10)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2496.
2. Park Y-W, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
4. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344: 1343-1350.
5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346: 393-403.
6. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
7. National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res. 1998;6:51S-209S.
8. Buchanan T, Xiang A, Peters R, et al. Prevention of type 2 diabetes by treatment of insulin resistance: comparison of early vs late intervention in the TRIPOD study [abstract]. Diabetes. 2002;51(suppl 2):A35.
9. Miyazaki Y, DeFronzo PA. Effect of piogfitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87: 2784-2791.
10. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104-1109.